Key Updates in the Management of Small Cell Lung Cancer
Ryan Haumschild, PharmD, MS, MBA; Anne Chiang, MD, PhD; Afshin Dowlati, MD; Jacob Sands, MD; and Wade Iams, MD, explore recent advances in small cell lung cancer (SCLC) management, discussing staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery.
Episodes
September 27th 2024EP. 1: Introduction: Risk Factors and Characteristics Defining SCLC
Panelists discuss how small cell lung cancer (SCLC) differs from non–small cell lung cancer in terms of staging, epidemiology, risk factors, prevention strategies, and prognosis, while also exploring the distinctions between limited-stage and extensive-stage SCLC and considering potential improvements in staging practices.
September 27th 2024EP. 2: Established Multidisciplinary Therapies for SCLC
Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.
October 4th 2024EP. 3: Immunotherapies for Extensive-Stage SCLC
Panelists discuss how immunotherapies like durvalumab and atezolizumab have emerged as promising treatments for extensive-stage small cell lung cancer (SCLC), complementing traditional chemotherapy, and explore the results of key trials such as CASPIAN and IMpower133 while considering patient selection, treatment algorithms, and management of adverse events associated with these novel therapies.
October 4th 2024EP. 4: Introducing Bispecifics for Extensive-Stage SCLC
Panelists discuss how tarlatamab, a bispecific T-cell engager therapy, received accelerated approval for extensive-stage small cell lung cancer (SCLC) in May 2024, examining its mechanism of action, pivotal clinical data, management of adverse events, practical considerations for administration, and its position within the SCLC treatment algorithm.
October 11th 2024EP. 5: Standard of Care Durvalumab for Limited-Stage SCLC
Panelists discuss how the ADRIATIC trial investigating durvalumab in limited-stage small cell lung cancer (SCLC) has shown promising results, potentially addressing unmet needs in this patient population, and consider its potential impact on treatment algorithms and its possible emergence as a new standard of care if approved for this indication.
October 11th 2024EP. 6: Additional Immunotherapies on the Horizon for LS-SCLC
Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.
